Back to top
more

Sarepta Therapeutics (SRPT)

(Delayed Data from NSDQ)

$148.98 USD

148.98
1,505,545

-3.69 (-2.42%)

Updated Jul 16, 2024 04:00 PM ET

After-Market: $148.88 -0.10 (-0.07%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.15%
2Buy17.88%
3Hold9.47%
4Sell5.14%
5Strong Sell2.57%
S&P50011.11%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

2-Buy of 5   2      

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

F Value D Growth A Momentum D VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 33% (83 out of 250)

Industry: Medical - Biomedical and Genetics

Better trading starts here.

Zacks News

Sarepta (SRPT) Q2 Earnings Miss, DMD Drugs' Sales Robust

Strong demand for Sarepta's (SRPT) DMD drugs boosts the top line in the second quarter. However, the wider-than-anticipated losses drive the stock down in after-market trading.

Sarepta Therapeutics (SRPT) Reports Q2 Loss, Tops Revenue Estimates

Sarepta Therapeutics (SRPT) delivered earnings and revenue surprises of -147.66% and 6.09%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?

Drug, Biotech Stocks' Q2 Earnings on Aug 2: GILD, INCY & More

Let's check out how the four pharma/drug/biotech companies are placed before the quarterly earnings release on Aug 2.

Strength Seen in Sarepta Therapeutics (SRPT): Can Its 8.2% Jump Turn into More Strength?

Sarepta Therapeutics (SRPT) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might help the stock continue moving higher in the near term.

Analysts Estimate Codexis (CDXS) to Report a Decline in Earnings: What to Look Out for

Codexis (CDXS) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Roche (RHHBY) 1H22 Earnings, Sales Grow, View Disappoints

Roche (RHHBY) performance in the first half was decent on demand for its diagnostics base business and new drugs. Demand for COVID-19 tests is likely to fall in the second half.

Incyte (INCY) Gets FDA Nod for Label Expansion of Opzelura

Incyte (INCY) Opzelura cream 1.5% gets FDA approval for another indication - nonsegmental vitiligo in adult and pediatric patients 12 years of age and older.

Novartis (NVS) Q2 Earnings Beat, Revenues Miss Estimates

Novartis (NVS) reports mixed results in the second quarter, as key brands maintain momentum but generic competition remains a drag.

Roche (RHHBY) Announces 2-Year Data on Vabysmo for nAMD

Roche's (RHHBY) new two-year data reinforce the long-term efficacy, safety and durability of Vabysmo in wet age-related mtacular degeneration.

NexImmune (NEXI) IND Gets Clearance for HPV-Related Cancer Drug

NexImmune (NEXI) gets FDA clearance for IND for drug for human papillomavirus (HPV)-related cancers.

Pluristem (PSTI) Phase III Study Misses Goal, Stock Down

Pluristem (PSTI) phase III study of muscle regeneration following hip fracture surgery evaluating PLX-PAD cells did not meet the primary endpoint. Consequently, the stock declines.

Here's Why Sarepta Therapeutics (SRPT) is a Great Momentum Stock to Buy

Does Sarepta Therapeutics (SRPT) have what it takes to be a top stock pick for momentum investors? Let's find out.

Is First Trust NYSE Arca Biotechnology ETF (FBT) a Strong ETF Right Now?

Smart Beta ETF report for FBT

Sarepta (SRPT) Down on Clinical Hold on DMD Candidate SRP-5051

The FDA places Sarepta's (SRPT) next-generation DMD candidate, SRP-5051, on clinical hold, following a report of hypomagnesemia in the ongoing phase II MOMENTUM study.

Why Is Sarepta Therapeutics (SRPT) Up 1.2% Since Last Earnings Report?

Sarepta Therapeutics (SRPT) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Bausch (BHC) Q1 Earnings and Revenues Miss, Stock Down

Bausch (BHC) misses on earnings and sales in the first quarter due to incremental macro pressures and a challenging supply chain environment.

Bayer (BAYRY) Earnings & Revenues Surpass Estimates in Q1

Bayer (BAYRY) beats estimates for both earnings and revenues in the first quarter of 2022.

Is First Trust NYSE Arca Biotechnology ETF (FBT) a Strong ETF Right Now?

Smart Beta ETF report for FBT

Sarepta (SRPT) Q1 Earnings Beat, DMD Drugs' Sales Robust

Strong demand for Sarepta's (SRPT) DMD drugs boosts its top line in the first quarter. Stock up in after-market trading.

Sarepta Therapeutics (SRPT) Reports Q1 Loss, Tops Revenue Estimates

Sarepta Therapeutics (SRPT) delivered earnings and revenue surprises of 11.11% and 3.59%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?

Sarepta Therapeutics (SRPT) May Report Negative Earnings: Know the Trend Ahead of Q1 Release

Sarepta Therapeutics (SRPT) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Why Is Sarepta Therapeutics (SRPT) Down 1.2% Since Last Earnings Report?

Sarepta Therapeutics (SRPT) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.